Alpha-Tocopherol

Alpha-Tocopherol

SCHEMBL3272328

Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2.O=C(O)C1CCCCC1C(=O)O

nearest known ligand 0.78

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.78
TTPA P49638 3/20 0.78
MAPT P10636 2/20 0.78
MEN1 O00255 2/20 0.78
KMT2A Q03164 2/20 0.78
GSTP1 P09211 1/20 0.78
USP2 O75604 1/20 0.78
THRB P10828 1/20 0.78
CYP2C9 P11712 1/20 0.78
CYP2C19 P33261 1/20 0.78
NR1I2 O75469 3/20 0.71
ALOX5 P09917 2/20 0.71
PSEN1 P49768 2/20 0.62
PDE4A P27815 1/20 0.62
PDE3A Q14432 1/20 0.62
GSTO1 P78417 2/20 0.60
PTPN1 P18031 1/20 0.60
AKT1 P31749 2/20 0.47
PDPK1 O15530 1/20 0.47
PHLPP1 O60346 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alpha-Tocopherol SCHEMBL28174565 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL28174566 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL27538180 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tochopherol SCHEMBL1879635 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL4083978 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL27696980 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL27177 0.89 LMNA (0.89) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL5868266 0.88 LMNA (0.88) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL460611 0.88 LMNA (0.88) LMNATTPAMAPTMEN1KMT2A
Alpha-Tocopherol SCHEMBL7584393 0.88 LMNA (0.74) LMNATTPAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682552-B1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS SONUS PHARMA INC (US) 2010-06-30 EP disclosed
US-20080045559-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS SONUS PHARMACEUTICALS, INC. (US) 2008-02-21 US disclosed
US-20070207196-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUND FORMULATIONS SONUS PHARMACEUTICALS, INC. (US) 2007-09-06 US disclosed
US-7223770-B2 Tocopherol-modified therapeutic drug compounds SONUS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20060229359-A1 Tocopherol-modified therapeutic drug compounds SONUS PHARMACEUTICALS, INC. (US) 2006-10-12 US disclosed
EP-1682552-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS SONUS PHARMACEUTICALS, INC. (US) 2006-07-26 EP disclosed
WO-2005042539-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS SONUS PHARMACEUTICALS, INC. (US) 2005-05-12 WO disclosed
US-20050096340-A1 lipophilic derivatives of paclitaxel, camptothecin, docetaxel or derivatives thereof; tocopherol succinate paclitaxel for example; emulsions for drug delivery, treating cancer; increased plasma elimination half-life compared to the parent therapeutic drug SONUS PHARMACEUTICALS, INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096340-A1 lipophilic derivatives of paclitaxel, camptothecin, docetaxel or derivatives thereof; tocopherol succinate paclitaxel for example; emulsions for drug delivery, treating cancer; increased plasma elimination half-life compared to the parent therapeutic drug TTPA, CPT2, CETP LMNA 417/4885TTPA 1/4885MAPT 192/4885
US-20060229359-A1 Tocopherol-modified therapeutic drug compounds TTPA, APOB, LRAT LMNA 564/4885TTPA 1/4885MAPT 389/4885
US-20070207196-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUND FORMULATIONS TTPA, APOB, LRAT LMNA 567/4885TTPA 1/4885MAPT 333/4885
US-20080045559-A1 TOCOPHEROL-MODIFIED THERAPEUTIC DRUG COMPOUNDS TTPA, APOB, LRAT LMNA 564/4885TTPA 1/4885MAPT 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.